In response to the rapidly evolving COVID-19 pandemic, the National Institutes of Health assembled a panel of experts (the Panel), including physicians, biostatisticians, clinical pharmacists, and other experts, to provide practical recommendations for health care providers and issued the first version of the COVID-19 Treatment Guidelines on April 21, 2020. For close to 4 years, the Panel has critically reviewed the growing body of research data on COVID-19 and used that information to develop and revise their recommendations for treating patients with this disease.
Many pharmacists have made significant contributions to the Panel:
- Pamela Belperio, Pharm.D., BCPS – Department of Veterans Affairs
- Sarita Boyd, Pharm.D. – Food and Drug Administration
- Page Crew, Pharm.D., MPH – Food and Drug Administration
- Susan L. Davis, Pharm.D., FIDP – Wayne State University, Henry Ford Health System
- Amy L. Dzierba, Pharm.D., FCCM, FCCP, BCCCP – New York-Presbyterian Hospital
- Gregory Eschenauer, Pharm.D. – University of Michigan
- Jomy George, Pharm.D. – National Institutes of Health
- Steve Grapentine, Pharm.D. – UCSF Benioff Children's Hospital San Francisco
- Safia Kuriakose, Pharm.D. – NIAID – Assistant Executive Secretary of the Panel
- Christine Macbrayne, Pharm.D., MSCS – Children's Hospital Colorado
- Alice K. Pau, Pharm.D. – National Institutes of Health – Executive Secretary of the Panel
- Kimberly Scarsi, Pharm.D. – University of Nebraska Medical Center
Several members were tasked with developing drug-drug interaction guidance for the use of ritonavir-boosted nirmatrelvir. This page of the guidelines has been the most viewed section of the guidelines since it was released in December 2021, with over 2.6 million page views to date.
The federal COVID-19 Public Health Emergency ended in May 2023. The last update of the guidelines will be published in early 2024. The guidelines website will remain available for several months following the final update and will provide a downloadable version of the final publication.